Novartis Projects 5-6% Sales CAGR 2025-2030
Ticker: NVSEF · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: guidance, pipeline, sales-growth, pharmaceuticals
TL;DR
Novartis ups sales forecast to 5-6% CAGR (2025-2030) on strong pipeline & drug upgrades.
AI Summary
Novartis AG announced on November 20, 2025, that it projects a 5-6% compound annual growth rate (CAGR) in constant currency (cc) sales from 2025 to 2030. This mid-term guidance was rolled forward following an upgrade of its 2024-2029 guidance to 6% cc. The company also upgraded peak sales guidance for its drugs Kisqali and Scemblix, now identifying eight de-risked, in-market assets with peak sales potential between USD 3 billion and USD 10 billion.
Why It Matters
This updated guidance suggests continued strong performance and growth for Novartis, driven by its promising pipeline and established products, potentially impacting investor confidence and market share.
Risk Assessment
Risk Level: low — The filing provides forward-looking guidance and updates on existing products, which is standard for a company of this size and does not indicate immediate significant risks.
Key Numbers
- +5-6% — cc sales CAGR (Projected compound annual growth rate for sales from 2025-2030)
- +6% — cc sales CAGR (Upgraded guidance for 2024-2029)
- 8 — de-risked assets (Number of in-market assets with significant peak sales potential)
Key Players & Entities
- Novartis AG (company) — Registrant and subject of the report
- Kisqali (drug) — Drug with upgraded peak sales guidance
- Scemblix (drug) — Drug with upgraded peak sales guidance
- USD 3 billion (dollar_amount) — Lower end of peak sales potential for de-risked assets
- USD 10 billion (dollar_amount) — Upper end of peak sales potential for de-risked assets
FAQ
What is Novartis's updated mid-term sales growth projection?
Novartis projects a 5-6% compound annual growth rate (CAGR) in constant currency (cc) sales for the period 2025-2030.
What is the reason for the updated sales guidance?
The guidance was rolled forward following an upgrade of the 2024-2029 guidance to 6% cc.
Which specific drugs have seen their peak sales guidance upgraded?
Peak sales guidance has been upgraded for Kisqali and Scemblix.
How many de-risked, in-market assets does Novartis now have with significant peak sales potential?
Novartis now has eight de-risked, in-market assets with peak sales potential between USD 3 billion and USD 10 billion.
What is the filing date and the period of report for this 6-K?
The filing is dated November 20, 2025, and the period of report is also November 20, 2025.
Filing Stats: 2,016 words · 8 min read · ~7 pages · Grade level 16.9 · Accepted 2025-11-20 06:05:05
Filing Documents
- f6k_112025.htm (6-K) — 33KB
- hdr.jpg (GRAPHIC) — 3KB
- logo.jpg (GRAPHIC) — 23KB
- 0001171843-25-007445.txt ( ) — 70KB
forward-looking statements as a result of new information, future events or otherwise
forward-looking statements as a result of new information, future events or otherwise. Additional information and Where to Find It On October 26, 2025, Novartis announced an agreement to acquire Avidity Biosciences, Inc. Under the terms of the transactions, Novartis, through a merger with a newly formed indirect wholly owned subsidiary, will acquire all outstanding shares of Avidity. The transaction is expected to close in the first half of 2026, subject to the completion of the spin-off or a sale by Avidity of SpinCo and other customary closing conditions, including receipt of regulatory approvals and the approval of Avidity stockholders. In connection with the spin-off or sale of SpinCo and the merger (the "Transactions"), Novartis, Avidity and SpinCo intend to file relevant documents with the Securities and Exchange Commission (the "SEC"), including a preliminary and definitive proxy statement to be filed by Avidity. The definitive proxy statement and proxy card will be delivered to the stockholders of Avidity in advance of the special meeting relating to the Transactions. This document is not a substitute for the proxy statement or any other document that may be filed by Avidity with the SEC. AVIDITY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF NOVARTIS AND AVIDITY WITH THE SEC IN CONNECTION WITH THE TRANSACTIONS OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES TO THE TRANSACTIONS. Investors and security holders will be able to obtain a free copy of the proxy statement and such other documents containing important information about Novartis and Avidity, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Novartis and Avidity make available free of charge at the Novartis website at www.novartis.com/investors/financial-data/sec
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Novartis AG Date: November 20, 2025 By: /s/ PAUL PENEPENT Name: Paul Penepent Title: Head of Financial Reporting and Accounting